The present invention concerns the prototypical pharmacologic profile of GABA-stearamide, GABA-palmitamide, GABA-linoleamide and Progabide characterized by their interesting positive modulation of at least one γ-aminobutyric acid A receptor being GABA (A) and GABA (B), which are principally extrasynaptic, for treating a neurodegenerative or neurodevelopmental disease. The present invention further originating brain pro-GABAergic and anti-glutamatergic activities and also an unique pharmacological profile which antagonize all the components of the vicious circle generated in the brain by the Glutamate/GABA imbalance, with protective and preventive action against all the behavioral abnormalities, the cognitive deficits and neurotoxicities, in neurodegenerative (Alzheimers, Parkinsons Huntingtons and Multiple Sclerosis) diseases and neurodevelopmental diseases (Autism spectrum desorders and related syndroms).
